-
公开(公告)号：US20230250105A1
公开(公告)日：2023-08-10
申请号：US18175030
申请日：2023-02-27
申请人： UCB Biopharma SRL , SANOFI
发明人： Daniel Christopher Brookings , Teresa De Haro Garcia , Yann Foricher , Helen Tracey Horsley , Martin Clive Hutchings , James Andrew Johnson , Malcolm Maccoss , Mengyang Xuan , Zhaoning Zhu
IPC分类号： C07D487/18
CPC分类号： C07D487/18 , C07B2200/05
摘要： A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US20210252012A1
公开(公告)日：2021-08-19
申请号：US17176018
申请日：2021-02-15
申请人： UCB Biopharma SRL , SANOFI
发明人： Daniel Christopher Brookings , Teresa De Haro Garcia , Yann Foricher , Helen Tracey Horsley , Martin Clive Hutchings , James Andrew Johnson , Malcolm Maccoss , Mengyang Xuan , Zhaoning Zhu
IPC分类号： A61K31/55 , C07D487/18
摘要： A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US11912721B2
公开(公告)日：2024-02-27
申请号：US17102790
申请日：2020-11-24
申请人： UCB Biopharma SRL , Sanofi
发明人： Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm MacCoss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC分类号： C07D519/00 , C07D491/08 , C07D487/08 , C07D491/18 , C07D495/08 , C07D471/18 , C07D487/18 , C07D493/18 , C07D495/18 , C07D513/18 , C07F7/18 , A61K31/4184 , A61K31/506 , A61K31/55
CPC分类号： C07D519/00 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D471/18 , C07D487/08 , C07D487/18 , C07D491/08 , C07D491/18 , C07D493/18 , C07D495/08 , C07D495/18 , C07D513/18 , C07F7/1804
摘要： A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号：US20210361668A1
公开(公告)日：2021-11-25
申请号：US17284950
申请日：2019-10-23
申请人： UCB Biopharma SRL , SANOFI
IPC分类号： A61K31/55 , C07D471/18
摘要： A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNF a activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US20210155637A1
公开(公告)日：2021-05-27
申请号：US17102790
申请日：2020-11-24
申请人： UCB Biopharma SRL , Sanofi
发明人： Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC分类号： C07D519/00 , C07F7/18 , C07D491/08 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D487/08 , C07D491/18 , C07D495/08 , C07D471/18 , C07D487/18 , C07D493/18 , C07D495/18 , C07D513/18
摘要： A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号：US10953019B2
公开(公告)日：2021-03-23
申请号：US16487988
申请日：2018-03-14
申请人： UCB Biopharma SRL , Sanofi
发明人： Julien Alistair Brown , Daniel Christopher Brookings , Jag Paul Heer , James Andrew Johnson , Zhaoning Zhu
IPC分类号： A61K31/55 , C07D471/22
摘要： A series of substituted fused pentacyclic imidazopyridine and imidazopyridazine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US11554122B2
公开(公告)日：2023-01-17
申请号：US17284950
申请日：2019-10-23
申请人： UCB Biopharma SRL , SANOFI
IPC分类号： A61K31/55 , C07D471/18 , C07D487/18
摘要： A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNF a activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US10906919B2
公开(公告)日：2021-02-02
申请号：US16220847
申请日：2018-12-14
申请人： UCB Biopharma SRL , Sanofi
发明人： Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC分类号： C07D519/00 , C07F7/18 , C07D491/08 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D487/08 , C07D491/18 , C07D495/08 , C07D471/18 , C07D487/18 , C07D493/18 , C07D495/18 , C07D513/18
摘要： A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号：US10980814B2
公开(公告)日：2021-04-20
申请号：US16497217
申请日：2018-04-24
申请人： UCB Biopharma SRL , SANOFI
发明人： Daniel Christopher Brookings , Teresa De Haro Garcia , Yann Foricher , Helen Tracey Horsley , Martin Clive Hutchings , James Andrew Johnson , Malcolm Maccoss , Mengyang Xuan , Zhaoning Zhu
IPC分类号： C07D487/18 , A61K31/55
摘要： Disclosed herein are compounds of formula (I) and pharmaceutically acceptable salt thereof, wherein variables X, R1, R2, and R3 are defined herein. These compounds are potent modulators of human TNFα activity and, accordingly, of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US20240140951A1
公开(公告)日：2024-05-02
申请号：US18267235
申请日：2021-12-06
申请人： UCB Biopharma SRL
发明人： Gareth Neil Brace , Shuyu Chu , Anne Marie Foley , James Andrew Johnson , Timothy John Norman , Joanna Rachel Quincey , James Thomas Reuberson , Robert Straker , Robert James Townsend
IPC分类号： C07D487/04 , A61P29/00 , C07D519/00
CPC分类号： C07D487/04 , A61P29/00 , C07D519/00
摘要： A series of substituted imidazo[1,2-b]pyridazine derivatives as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.018 秒)
